Form 4 for IMDX Insight Molecular Diagnostics Inc.

Accepted 2022-03-17 00:00:00 ET · period of report 2022-03-15 · accession 0001493152-22-007206 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-03-17	2022-03-17	IMDX	Paulsen Gisela	COO	P - Purchase	$1.20	+16.5K	16.5K	New	+$19.8K
DM	2022-03-17	2022-03-15	IMDX	Paulsen Gisela	COO	A - Grant	$0.00	+250.0K	125.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock, no par value	2022-03-17	P	A	16,500	$1.20	16,500	D	—	—	(F1) The price of $1.198 per share represents a weighted average of prices ranging from $1.180 to $1.200 per share. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price
2	Derivative	Option to Purchase Common Stock	2022-03-15	A	A	125,000	$0.00	125,000	D	$1.15 · — to 2032-03-15	125,000 Common Stock	(F3) Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.
3	Derivative	Option to Purchase Common Stock	2022-03-15	A	A	125,000	$0.00	125,000	D	$1.15 · — to 2032-03-15	125,000 Common Stock	(F2) 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.